MCID: KDN018
MIFTS: 66

Kidney Disease malady

Categories: Nephrological diseases, Genetic diseases

Aliases & Classifications for Kidney Disease

Summaries for Kidney Disease

MedlinePlus : 41 healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. they also make hormones that keep your bones strong and your blood healthy. but if the kidneys are damaged, they don't work properly. harmful wastes can build up in your body. your blood pressure may rise. your body may retain excess fluid and not make enough red blood cells. this is called kidney failure. if your kidneys fail, you need treatment to replace the work they normally do. the treatment options are dialysis or a kidney transplant. each treatment has benefits and drawbacks. no matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. but with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. nih: national institute of diabetes and digestive and kidney diseases

MalaCards based summary : Kidney Disease, also known as kidney diseases, is related to hemorrhoid and systolic heart failure, and has symptoms including polyuria An important gene associated with Kidney Disease is PKD1 (Polycystin 1, Transient Receptor Potential Channel Interacting). The drugs Heparin and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and liver, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 71 Kidney disease, also known as nephropathy or renal disease, is damage to or disease of a kidney.... more...

Related Diseases for Kidney Disease

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 534)
id Related Disease Score Top Affiliating Genes
1 hemorrhoid 31.1 B2M PKDREJ REN
2 systolic heart failure 30.1 ACE B2M UMOD
3 antiphospholipid syndrome 29.4 ALB REN
4 pericarditis 29.3 ACE ALB CST3 REN
5 calcinosis 29.2 ACE ALB B2M CST3 EPO FGF23
6 autosomal dominant polycystic kidney disease 12.3
7 cystic kidney disease 12.3
8 epilepsy, progressive myoclonic 4, with or without renal failure 12.3
9 polycystic kidney disease 12.2
10 polycystic kidney disease 2 12.2
11 medullary cystic kidney disease 2 12.2
12 polycystic kidney disease, adult type i 12.1
13 autosomal dominant medullary cystic kidney disease with hyperuricemia 12.1
14 medullary cystic kidney disease 1 12.1
15 bifid nose with or without anorectal and renal anomalies 12.1
16 autosomal dominant medullary cystic kidney disease without hyperuricemia 12.1
17 polycystic kidney disease 3 12.1
18 ventriculomegaly with cystic kidney disease 12.0
19 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.0
20 autoimmune interstitial lung, joint, and kidney disease 12.0
21 ren-related kidney disease 11.9
22 chronic kidney failure 11.9
23 polycystic kidney and hepatic disease 11.9
24 autosomal dominant tubulointerstitial kidney disease, muc1-related 11.9
25 autosomal dominant tubulointerstitial kidney disease, umod-related 11.9
26 igg4-related kidney disease 11.8
27 polycystic kidney disease, infantile severe, with tuberous sclerosis 11.8
28 malignant hypertensive renal disease 11.8
29 nephronophthisis 11.8
30 polycyctic kidney disease 3 11.7
31 benign hypertensive renal disease 11.7
32 familial juvenile hyperuricaemic nephropathy 11.7
33 autosomal dominant tubulointerstitial kidney disease, ren-related 11.7
34 polycystic kidney disease 1, autosomal dominant 11.7
35 polycystic kidney disease 2, autosomal dominant 11.7
36 end stage renal failure 11.6
37 renal osteodystrophy 11.5
38 renal cysts and diabetes syndrome 11.3
39 medullary sponge kidney 11.2
40 alport syndrome 11.1
41 glomerulonephritis 11.0
42 polycystic liver disease 10.9
43 dent disease 10.9
44 obesity 10.9
45 tuberous sclerosis 10.8
46 nephrolithiasis 10.8
47 hepatitis c 10.8
48 calciphylaxis 10.8
49 orofaciodigital syndrome i 10.8
50 pancreatitis 10.8

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Bladder Neck Obstruction
Bronchitis Bronchopneumonia
Cardiac Arrest Cardiogenic Shock
Chronic Kidney Failure Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Diabetic Polyneuropathy Encephalopathy
Esophagitis Familial Atrial Fibrillation
First-Degree Atrioventricular Block Generalized Atherosclerosis
Gout Heart Disease
Hydronephrosis Hypertension, Essential
Hypoglycemia Hypoglycemic Coma
Hypothyroidism Intermediate Coronary Syndrome
Intestinal Obstruction Iron Deficiency Anemia
Ischemic Heart Disease Left Ventricular Outflow Tract Obstruction
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Familial Primary, 1, with or Without Hht Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease

Symptoms & Phenotypes for Kidney Disease

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ACE B2M COL4A5 CST3 EPO FGF23
2 homeostasis/metabolism MP:0005376 10.28 NPHS2 PKD1 PKD1L1 PKD2 PKD2L2 REN
3 growth/size/body region MP:0005378 10.17 ACE B2M FGF23 IFT88 NPHS2 PKD1
4 mortality/aging MP:0010768 10.1 ACE ALB B2M COL4A5 CST3 EPO
5 immune system MP:0005387 10.07 FGF23 PKD1 PKD2 PKHD1 REN UMOD
6 digestive/alimentary MP:0005381 10.06 ALB B2M FGF23 IFT88 PKD1 PKD1L1
7 renal/urinary system MP:0005367 9.93 NPHS2 PKD1 PKD1L1 PKD2 PKHD1 REN
8 liver/biliary system MP:0005370 9.92 ACE ALB PKHD1 B2M EPO IFT88
9 reproductive system MP:0005389 9.61 ACE B2M CST3 FGF23 PKD1 PKD1L1
10 respiratory system MP:0005388 9.17 EPO FGF23 IFT88 PKD1 PKD1L1 PKD2

Drugs & Therapeutics for Kidney Disease

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1134)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 9005-49-6 772 46507594
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Theophylline Approved Phase 4,Phase 2,Phase 3 58-55-9 2153
4
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 4205-90-7 2803
5
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Phase 1 10102-43-9 145068
6
Baclofen Approved Phase 4 1134-47-0 2284
7
Rosiglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 122320-73-4 77999
8
Ezetimibe Approved Phase 4 163222-33-1 150311
9
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 111025-46-8 4829
10
Simvastatin Approved Phase 4,Phase 3 79902-63-9 54454
11
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7440-66-6 32051 23994
12
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
13
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 104987-11-3 445643 439492
14
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
15
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
16
Digoxin Approved Phase 4 20830-75-5 30322 2724385
17
Colchicine Approved Phase 4,Phase 2,Phase 1 64-86-8 6167 2833
18
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
19
Lopinavir Approved Phase 4,Phase 3 192725-17-0 92727
20
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
21
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
22
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
23
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
24
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2 54-31-9 3440
25
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 24280-93-1 446541
26
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 128794-94-5 5281078
27
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
28
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
29
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 75847-73-3 5362032 40466924
30
Ramipril Approved Phase 4,Phase 3,Phase 2 87333-19-5 5362129
31
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
32
Fosinopril Approved Phase 4,Phase 3,Phase 2 98048-97-6 55891
33
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1 76420-72-9 6917719
34
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114798-26-4 3961
35
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1952-01-7, 52-01-7 5833
36
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 137862-53-4 60846
37
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-93-5 3639
38
Candesartan Approved Phase 4,Phase 3,Phase 2,Phase 1 139481-59-7 2541
39
Amlodipine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 88150-42-9 2162
40
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138402-11-6 3749
41
Atenolol Approved Phase 4,Phase 3,Early Phase 1 29122-68-7 2249
42
Isosorbide Dinitrate Approved Phase 4 87-33-2 6883
43 Moxonidine Approved Phase 4 75438-57-2 4810
44
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
45
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
46
Triamterene Approved Phase 4 396-01-0 5546
47
Alendronate Approved Phase 4,Phase 3 121268-17-5, 66376-36-1 2088
48
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 446-86-6 2265
49
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1 36791-04-5 37542
50
Allopurinol Approved Phase 4,Phase 3,Phase 2,Phase 1 315-30-0 2094

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4
4 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4
5 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4
6 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
7 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4
8 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4
9 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4
10 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4
11 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4
12 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4
13 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
14 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4
15 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4
16 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4
17 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4
18 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4
19 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
20 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4
21 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4
22 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4
23 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4
24 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4
25 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4
26 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
27 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4
28 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Unknown status NCT01198379 Phase 4
29 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4
30 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
31 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4
32 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
33 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4
34 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4
35 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4
36 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4
37 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4
38 Revascularization of Renal Artery Stenosis Versus Medical Therapy for the Treatment of Ischemic Nephropathy Unknown status NCT01023373 Phase 4
39 Far Infrared Therapy on AV Fistula Flow, Endothelial Function and Echocardiography in ESRD Patients Unknown status NCT01138254 Phase 4
40 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4
41 Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease Unknown status NCT00852787 Phase 4
42 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4
43 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4
44 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4
45 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4
46 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4
47 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4
48 A Study Comparing Outcomes of Kidney Transplants in Patients on Steroids Versus Those Who Discontinue Steroids Unknown status NCT00273559 Phase 4
49 Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4
50 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: kidney diseases

Genetic Tests for Kidney Disease

Genetic tests related to Kidney Disease:

id Genetic test Affiliating Genes
1 Abnormality of the Kidney 29
2 Nephropathy 29

Anatomical Context for Kidney Disease

MalaCards organs/tissues related to Kidney Disease:

39
Kidney, Bone, Liver, Heart, Endothelial, Neutrophil, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

18
The Kidney

Publications for Kidney Disease

Articles related to Kidney Disease:

(show top 50) (show all 3748)
id Title Authors Year
1
The Challenges of Treating Cancer Patients on Hemodialysis, or With Chronic Kidney Disease. ( 28090621 )
2017
2
Traditional Medicines and Kidney Disease in Low- and Middle-Income Countries: Opportunities and Challenges. ( 28532554 )
2017
3
Acute and chronic kidney disease in elderly patients with hip fracture: prevalence, risk factors and outcome with development and validation of a risk prediction model for acute kidney injury. ( 28088181 )
2017
4
Disorders of fatty acid oxidation and autosomal recessive polycystic kidney disease-different clinical entities and comparable perinatal renal abnormalities. ( 28083701 )
2017
5
Acute aortic syndrome in autosomal dominant polycystic kidney disease. ( 28087011 )
2017
6
Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia. ( 28382567 )
2017
7
Kidney disease and obesity: epidemiology, mechanisms and treatment. ( 28090083 )
2017
8
AJKD Atlas of Renal Pathology: Kidney Disease in Primary SjAPgren Syndrome. ( 28532640 )
2017
9
Restenosis in Hemodialytic Fistulas and Chronic Kidney Disease-Associated Vascular Disease: Two Pathologies Driven by Metakaryotic Stem Cells. ( 28535522 )
2017
10
Prevalence and risk factors for cardiovascular disease among chronic kidney disease patients: results from the Chinese cohort study of chronic kidney disease (C-STRIDE). ( 28088175 )
2017
11
Correlations of Plasma Desphosphorylated Uncarboxylated Matrix Gla Protein with Vascular Calcification and Vascular Stiffness in Chronic Kidney Disease. ( 27951533 )
2017
12
Association of H. pylori infection with chronic kidney disease among Chinese adults. ( 28044235 )
2017
13
CE: Improving Outcomes for Patients with Chronic Kidney Disease: Part 1. ( 28085685 )
2017
14
Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. ( 28003083 )
2017
15
Effect of renal denervation on kidney function in patients with chronic kidney disease. ( 28089459 )
2017
16
Association of genetic variants of pentraxin 3 rs3816527 with hypertension in Chronic kidney disease patients. ( 27838804 )
2017
17
The China Kidney Disease Network (CK-NET): "Big Data-Big Dreams". ( 28532632 )
2017
18
Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease. ( 28533541 )
2017
19
Chronic Kidney Disease, Gender, and Access to Care: A Global Perspective. ( 28532558 )
2017
20
Incidence, Development, and Prognosis of Diabetic Kidney Disease in China: Design and Methods. ( 28091412 )
2017
21
Chronic kidney disease in Chinese postmenopausal women: A cross-sectional survey. ( 28091429 )
2017
22
Phosphate in Chronic Kidney Disease Progression. ( 28535520 )
2017
23
Person-centred care in chronic kidney disease: a cross-sectional study of patients' desires for self-management support. ( 28086812 )
2017
24
Improving kidney disease in obese adolescents: a surgical approach. ( 28087009 )
2017
25
Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. ( 28532709 )
2017
26
Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. ( 28063122 )
2017
27
Genetics and Autosomal Dominant Polycystic Kidney Disease Progression. ( 28535524 )
2017
28
Polycystic kidney disease: Autophagy boost to treat ADPKD? ( 28090082 )
2017
29
Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. ( 28403201 )
2017
30
Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease. ( 28088190 )
2017
31
China Kidney Disease Network (CK-NET) 2014 Annual Data Report. ( 28532549 )
2017
32
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia. ( 28042744 )
2017
33
High hepatitis C viral load and genotype 2 are strong predictors of chronic kidney disease. ( 28532708 )
2017
34
Focal segmental glomerulosclerosis in atypical polycystic kidney disease. ( 28063418 )
2017
35
Sodium and fluid management in the conservative management of Chronic Kidney Disease. ( 28090763 )
2017
36
Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. ( 27998644 )
2017
37
Fatal proteinuric kidney disease in a 30-month-old German Fleckvieh heifer caused by unilateral focal segmental glomerulosclerosis subsequent to a non-functional counterpart kidney. ( 28248187 )
2017
38
Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. ( 28532702 )
2017
39
Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. ( 28055049 )
2017
40
Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. ( 27165564 )
2017
41
Circulating Modified Metabolites and a Risk of ESRD in Patients With Type 1 Diabetes and Chronic Kidney Disease. ( 28087576 )
2017
42
Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans. ( 28534128 )
2017
43
A prospective cohort study of insomnia and chronic kidney disease in Japanese workers. ( 28534280 )
2017
44
Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative. ( 28091865 )
2017
45
The Potential Impact of Public Health Interventions in Preventing Kidney Disease. ( 28532553 )
2017
46
A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria. ( 28088187 )
2017
47
Trends in healthcare expenditure in United States adults with chronic kidney disease: 2002-2011. ( 28532412 )
2017
48
Breaking the ice: urine proteomics of medullary sponge kidney disease. ( 28087010 )
2017
49
Dietary salt restriction is beneficial to the management of autosomal dominant polycysticA kidney disease. ( 27993381 )
2017
50
Proteomic-based research strategy identified laminin subunit alpha 2 as a potential urinary-specific biomarker for the medullary sponge kidney disease. ( 27914711 )
2017